 |
VasoMedical Sponsors Launch of the International EECP® Society |
Dr. William E. Lawson, Professor of Medicine and Chief of the Division of Cardiology at Stony Brook University Presenting
EECP Experts Unveiling the Logo for the IEECPS
Dr. Ivan V. Shashenkov from Russia presenting
The International EECP® Society to Serve as the Premier Not-for-Profit Organization Championing Awareness for EECP® Therapy Around the World
WESTBURY, N.Y. – October 29, 2013 – VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced this week that it has co-sponsored the launch of the International EECP® Society (IEECPS) at the 3rd International EECP® Symposium in Beijing, China as announced last week on the Society's web site. IEECPS is an independent not-for-profit association comprised of leading physicians, researchers and other professionals involved in Enhanced External Counterpulsation (EECP) Therapy from around the world. The goal of the Society is to promote excellence in the noninvasive treatment of cardiovascular diseases through physician education, research, increased patient awareness, representation, and the advancement of quality patient care with EECP® therapy.
The formation of IEECPS was officially announced during the 3rd International EECP® Symposium held in conjunction with the 24th Great Wall International Congress of Cardiology and Asian Pacific Heart Congress, which VasoMedical attended. The 3rd International EECP® Symposium was organized by a group of cardiovascular experts including Dr. Hu Dayi, President of the Great Wall International Congress of Cardiology, Dr. C. Richard Conti, President Emeritus of the American College of Cardiology, Dr. William E. Lawson, Dr. GuiFu Wu and Dr. John CK Hui, an internationally recognized EECP® expert. Dr. William E. Lawson, Professor of Medicine and Chief of the Division of Cardiology at Stony Brook University, New York, USA was selected as the Society's first president. Dr. Guifu Wu, President and Director of the Fourth People's Hospital of Shenzhen, China was elected as Vice President of the Society. Many leading international experts in cardiology as well as in EECP® therapy participated in the Society's preparation meeting during the Symposium and joined the Society, signaling great support for EECP® therapy.
“EECP® Therapy has been around for nearly two decades. However, until now there wasn't a professional organization to bring together all of the experts and advocates of this treatment to help further awareness and adoption of the Therapy. The formation of the IEECPS is the result of the EECP® Therapy community finally coming together to review the science and initiate a program promoting an increased level of global understanding and acceptance of this treatment among healthcare providers,” said CEO of VasoMedical, Dr. Jun Ma.
Dr. Ma continued, “VasoMedical sponsored the launch of IEECPS because we understand the need for this organization and believe the Society will provide a great platform for influencing key opinion leaders and decision makers about the importance of EECP® Therapy and ultimately, grow the market for EECP® Therapy in the U.S. and abroad.”
The IEECPS will take a proactive role in educating doctors, cardiologists and other members of the healthcare community about the benefits of EECP® Therapy by disseminating newsletters as well as by organizing and hosting conferences and symposiums worldwide. Also, the IEECPS will focus its outreach efforts on promoting patient awareness in order to increase acceptance of the Therapy.
For more information about VasoMedical, please visit: www.vasomedical.com or www.eecp.com
For more information about IEECPS, please visit: www.ieecps.org
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com